| Bioactivity | Muraglitazar is a PPAR α/γ dual agonist for the treatment of type 2 diabetes and associated dyslipidemia. Muraglitazar shows potent activity in vitro at human PPARα (EC50 = 320 nM) and PPARγ(EC50 = 110 nM)[1]. |
| Name | Muraglitazar |
| CAS | 331741-94-7 |
| Formula | C29H28N2O7 |
| Molar Mass | 516.54 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Buse JB, Rubin CJ, Frederich R, et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther. 2005;27(8):1181-1195. [2]. Cox SL. Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia. Drugs Today (Barc). 2005;41(9):579-587. |
Muraglitazar
CAS: 331741-94-7 F: C29H28N2O7 W: 516.54
Muraglitazar is a PPAR α/γ dual agonist for the treatment of type 2 diabetes and associated dyslipidemia.Muraglitazar
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.